Anokion Revenue and Competitors
Estimated Revenue & Valuation
- Anokion's estimated annual revenue is currently $3.7M per year.
- Anokion's estimated revenue per employee is $77,500
- Anokion's total funding is $77.6M.
Employee Data
- Anokion has 48 Employees.
- Anokion grew their employee count by -21% last year.
Anokion's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and President | Reveal Email/Phone |
2 | SVP Corporate Development & Business Operations | Reveal Email/Phone |
3 | SVP, Clinical Operations | Reveal Email/Phone |
4 | VP Finance | Reveal Email/Phone |
5 | Senior Director, Finance | Reveal Email/Phone |
6 | Chief Scientific Officer | Reveal Email/Phone |
7 | Senior Director, Controller | Reveal Email/Phone |
8 | Chief Strategy Officer | Reveal Email/Phone |
9 | Senior Director, Clinical Operations | Reveal Email/Phone |
10 | Administrative Manager | Reveal Email/Phone |
Anokion Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Anokion?
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company?s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion?s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications. www.anokion.com
keywords:N/A
$77.6M
Total Funding
48
Number of Employees
$3.7M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Anokion News
Avik Pharmaceutical Ltd., ImmunogenX, LLC., ImmusanT, Institute for Protein Design, Anokion, Protagonist Therapeutics, Inc.,...
Anokion is a Swiss biotech company focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokin's distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tol ...
Based in Ecublens (VD), Anokion is developing a new therapy for treating rare autoimmune diseases such as celiac disease, multiple sclerosis and type 1 diabetes by restoring normal immune tolerance. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural ...
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, completed a $40m Series B financing. Backers included Versant Ventures, Novartis Venture Fund, Novo Ventures and select Swiss-based private investors. Celgene, which has an exi ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.4M | 48 | -20% | N/A |
#2 | $13.3M | 48 | -36% | N/A |
#3 | $7.4M | 48 | -2% | N/A |
#4 | $3.7M | 48 | 26% | N/A |
#5 | $5.6M | 48 | 9% | N/A |